SCHEMBL6034129

SCHEMBL6034129

Cc1ccc(Oc2cccc(C(N)CS(=O)(=O)O)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTGS1 P23219 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
CYP2C9 P11712 2/20 0.41
LTA4H P09960 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALOX5 P09917 1/20 0.40
FFAR1 O14842 2/20 0.40
ALDH1A1 P00352 1/20 0.40
FFAR4 Q5NUL3 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CYP2D6 P10635 1/20 0.39
MMP13 P45452 2/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422777 0.89 PTGS1 (0.50) PTGS1SMN1; SMN2LTA4HALOX5ALDH1A1
SCHEMBL6034137 0.87 FNTA (0.44) PTGS1LTA4HALOX5
SCHEMBL6420384 0.83 FNTA (0.47) PTGS1SMN1; SMN2LTA4HFFAR1KMT2A
SCHEMBL12905150 0.80 ACACB (0.46) HTTTDP1L3MBTL1PTGS1CYP2C9
SCHEMBL6927080 0.80 KMT2A (0.59) HTTTDP1L3MBTL1PTGS1SMN1; SMN2
SCHEMBL7086705 0.80 KMT2A (0.59) HTTTDP1L3MBTL1PTGS1SMN1; SMN2
SCHEMBL7090778 0.80 KMT2A (0.59) HTTTDP1L3MBTL1PTGS1SMN1; SMN2
SCHEMBL6419474 0.80 FDFT1 (0.45) HTTL3MBTL1SMN1; SMN2LTA4HALDH1A1
Hydrochloric Acid SCHEMBL20546770 0.79 KMT2A (0.57) HTTTDP1L3MBTL1PTGS1SMN1; SMN2
Hydrochloric Acid SCHEMBL7091447 0.79 KMT2A (0.57) HTTTDP1L3MBTL1PTGS1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1882375-A treatment of amyloid-and epileptogenesis-related diseases NEUROCHEM INTERNAT LTD (CH) 2006-12-20 CN disclosed
EP-1635909-A2 TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES Neurochem (International) Limited (CH) 2006-03-22 EP disclosed
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2005-02-17 US disclosed
WO-2005000406-A2 TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases APP, PSEN1, PSEN2 HTT 91/4885TDP1 1574/4885L3MBTL1 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.